Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Share-based Compensation (2021 - 2025)

Lyra Therapeutics has reported Share-based Compensation over the past 5 years, most recently at $562000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $562000.0 for Q4 2025, down 71.02% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (down 65.23% YoY), and the annual figure for FY2025 was $2.3 million, down 65.23%.
  • Share-based Compensation for Q4 2025 was $562000.0 at Lyra Therapeutics, up from $34000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for LYRA hit a ceiling of $2.2 million in Q1 2024 and a floor of $34000.0 in Q3 2025.
  • Median Share-based Compensation over the past 5 years was $1.1 million (2022), compared with a mean of $1.2 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 137.24% in 2022 and later plummeted 97.72% in 2025.
  • Lyra Therapeutics' Share-based Compensation stood at $782000.0 in 2021, then skyrocketed by 124.68% to $1.8 million in 2022, then dropped by 15.65% to $1.5 million in 2023, then soared by 30.84% to $1.9 million in 2024, then crashed by 71.02% to $562000.0 in 2025.
  • The last three reported values for Share-based Compensation were $562000.0 (Q4 2025), $34000.0 (Q3 2025), and $914000.0 (Q2 2025) per Business Quant data.